Search Results - "Schaber, Christopher J."

Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial by Kim, Ellen J, Mangold, Aaron R, DeSimone, Jennifer A, Wong, Henry K, Seminario-Vidal, Lucia, Guitart, Joan, Appel, James, Geskin, Larisa, Lain, Edward, Korman, Neil J, Zeitouni, Nathalie, Nikbakht, Neda, Dawes, Kenneth, Akilov, Oleg, Carter, Joi, Shinohara, Michi, Kuzel, Timothy M, Piette, Warren, Bhatia, Neal, Musiek, Amy, Pariser, David, Kim, Youn H, Elston, Dirk, Boh, Erin, Duvic, Madeleine, Huen, Auris, Pacheco, Theresa, Zwerner, Jeffrey P, Lee, Seung Tae, Girardi, Michael, Querfeld, Christiane, Bohjanen, Kimberly, Olsen, Elise, Wood, Gary S, Rumage, Adam, Donini, Oreola, Haulenbeek, Andrea, Schaber, Christopher J, Straube, Richard, Pullion, Christopher, Rook, Alain H, Poligone, Brian

“…Given that mycosis fungoides-cutaneous T-cell lymphoma (MF/CTCL) is chronic, there is a need for additional therapies with minimal short- and long-term adverse…”
Get more information

A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy by North, John R., Takenaka, Shunsuke, Rozek, Annett, Kielczewska, Agnieszka, Opal, Steven, Morici, Lisa A., Finlay, B.Brett, Schaber, Christopher J., Straube, Richard, Donini, Oreola

“…•The Innate Defense Regulator SGX94 acts on tissue-resident host immune cells.•Innate Defense Regulators have broad-spectrum activity against bacterial…”
Get full text

Compatibility study of topical 0.25% hypericin (HyBryteTM) application in subjects with mycosis fungoides: Results of the HPN‐CTCL‐02 study by Alexander‐Savino, Carolina V., Rumage, Adam, Pullion, Christopher, Straube, Richard, Schaber, Christopher J., Gilmore, Elaine S., Poligone, Brian

“…Background HyBryteTM is a photodynamic therapy of topical hypericin that has recently been shown to be safe and efficacious in early stage cutaneous T‐cell…”
Get full text

A Multicenter, Randomized, Controlled Trial of Lucinactant Versus Poractant Alfa Among Very Premature Infants at High Risk for Respiratory Distress Syndrome by Sinha, Sunil K, Lacaze-Masmonteil, Thierry, Valls i Soler, Adolf, Wiswell, Thomas E, Gadzinowski, Janusz, Hajdu, Julia, Bernstein, Graham, Sanchez-Luna, Manuel, Segal, Robert, Schaber, Christopher J, Massaro, Joseph, d'Agostino, Ralph, Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group

“…Available therapeutic surfactants are either animal-derived or non-protein-containing synthetic products. Animal-derived surfactants contain variable amounts…”
Get full text

A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants by Moya, Fernando R, Gadzinowski, Janusz, Bancalari, Eduardo, Salinas, Vicente, Kopelman, Benjamin, Bancalari, Aldo, Kornacka, Maria Katarzyna, Merritt, T. Allen, Segal, Robert, Schaber, Christopher J, Tsai, Huei, Massaro, Joseph, d'Agostino, Ralph, International Surfaxin Collaborative Study Group

“…Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved through the addition of peptides, such as sinapultide, that…”
Get full text

HyBryte™ use in early-stage cutaneous T-cell lymphoma by Poligone, Brian, Alexander-Savino, Carolina V., Kim, Ellen J., Mangold, Aaron R., Desimone, Jennifer, Wong, Henry K., Rumage, Adam T., Donini, Oreola, Haulenbeek, Andrea, Schaber, Christopher J., Straube, Richard, Pullion, Christopher, Rook, Alain H.

“…Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma of the skin, where at later stages skin-homing malignant T-cells affect lymph nodes,…”
Get full text